Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Atorvastatin attenuates the expression of damage-associated molecular patterns and inflammatory cytokines in patients with psoriasis.
Pharmacol Rep
March 2025
Second Department of Cardiology, Attikon University Hospital, Athens, Greece.
Background: In psoriasis, damage-associated molecular patterns (DAMPs) released by damaged local tissue act as danger signals and trigger inflammatory responses. Statins, in addition to cholesterol-lowering, have anti-inflammatory effects. We sought to assess the effectiveness of atorvastatin in attenuating plasma DAMPs and inflammatory cytokines in adults with psoriasis.
View Article and Find Full Text PDFDeucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.
J Eur Acad Dermatol Venereol
March 2025
Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, Connecticut, USA.
Background: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Objectives: To evaluate the safety and efficacy of deucravacitinib through 4 years in the Phase 3 POETYK PSO-1, PSO-2 and long-term extension (LTE) trials in psoriasis.
Methods: PSO-1 and PSO-2 (parent trials) randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily (QD) or apremilast 30 mg twice daily.
Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis.
JAMA Dermatol
February 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Importance: A critical need exists for developing a validated dermatologic-specific treatment satisfaction instrument.
Objective: To evaluate the structural validity, internal consistency, construct validity, and test-retest reliability of the 7-item dermatology-specific treatment satisfaction (DermSat-7) instrument in patients with psoriasis.
Design, Setting, And Participants: This survey study was conducted from July 2020 to April 2023 in dermatology outpatient clinics at the University of Southern California, Brigham and Women's Hospital, and Mount Sinai Union Square and included adults (aged ≥18 years) with psoriasis who were fluent in English.
Two-Week Low-Salt Diet Improves Acetylcholine-Induced Microvascular Dilation in Biologically Naïve Psoriasis Patients.
Nutrients
February 2025
Department of Dermatology and Venereology, University Hospital Osijek, J. Huttlera 4, HR-31000 Osijek, Croatia.
: Patients with psoriasis exhibit endothelial dysfunction (EDy), which increases their cardiovascular risk. Excessive salt intake impairs endothelium-dependent vascular reactivity. However, research on EDy in psoriasis has focused primarily on larger vessels, leaving skin microcirculation unexplored.
View Article and Find Full Text PDFShort-Term Oral Administration of 1.5 μg/kg bw/day of Deoxynivalenol Significantly Exacerbates Inflammatory and Itching Symptoms in a Mouse Model of Imiquimod-Induced Psoriasis.
Toxins (Basel)
January 2025
School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, Japan.
Deoxynivalenol (DON) is a mycotoxin commonly found worldwide and is implicated in various health effects. We recently demonstrated that subacute oral exposure to DON significantly exacerbates symptoms of type 2 helper T-cell-mediated allergic diseases in a model. We aim to investigate the role of oral DON exposure in type 17 helper T-cell-mediated immunoreactive diseases using a mouse psoriasis model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!